Glanzmann's thrombasthenia risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glanzmann's thrombasthenia}} | {{Glanzmann's thrombasthenia}} | ||
{{CMG}} {{AE}}{{OK}} | |||
==Overview== | ==Overview== |
Revision as of 21:44, 15 November 2018
Glanzmann's thrombasthenia |
Differentiating Glanzmann's thrombasthenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glanzmann's thrombasthenia risk factors On the Web |
American Roentgen Ray Society Images of Glanzmann's thrombasthenia risk factors |
Risk calculators and risk factors for Glanzmann's thrombasthenia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
The most potent risk factor in the heritable Glanzmann thrombasthenia is consanguineous marriage. [1]
Autoantibodies production cause of acquired Glanzmann thrombasthenia .
Risk Factors
Common risk factors that increase autoantibodies production in acquired Glanzmann thrombasthenia include:
- Hematologic disorders and malignancies, such as :
- Acute lymphoblastic leukemia
- Non-Hodgkin’s lymphoma
- Multiple myeloma
- Hairy cell leukemia
- Myelodysplastic syndrome
- Immune thrombocytopenic purpura (ITP)
- Autoimmune diseases, such as Lupus [2]
- Drugs : anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3
- Platelet transfusions. [3]
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMC 5922622. PMID 10.1002/ajh.20159 DOI: 10.1002/ajh.20159 Check
|pmid=
value (help). - ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). "Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies". Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.